Table 2.
Demographics and breast cancer treatment characteristics
| Characteristics | Total Sample (n=35) |
Control (n=16) |
Intervention (n=19) |
|---|---|---|---|
| Age at intervention (yr) | 46.1 ± 4.0 | 47.2 ± 3.8 | 45.1 ± 4.0 |
| Age at oophorectomy (yr) | 40.4 ± 4.0 | 40.7 ± 3.5 | 40.1 ± 4.4 |
| Time since diagnosis (yr) | 7.5 ± 4.6 | 9.4 ± 5.6 | 5.8 ± 2.5 |
| Race, no. (%) | |||
| White | 35 (100%) | 16 (100%) | 19 (100%) |
| Ethnicity, no. (%) | |||
| Hispanic | 2 (6%) | 2 (13%) | 0 (0%) |
| Non-Hispanic | 33 (94%) | 14 (87%) | 19 (100%) |
| Education, no. (%) | |||
| High school or less | 1 (3%) | 0 (0%) | 1 (5%) |
| Some college | 2 (6%) | 1 (6%) | 1 (5%) |
| College or more | 32 (91%) | 15 (94%) | 17 (90%) |
| Radiation (overall) | 14 (40%) | 7 (44%) | 7 (37%) |
| Radiation - Left | 7 (50%) | 2 (29%) | 5 (72%) |
| Radiation - Right | 4 (29%) | 3 (42%) | 1 (14%) |
| Radiation - Both | 3 (21%) | 2 (29%) | 1 (14%) |
| Chemotherapy (overall) | 29 (83%) | 15 (94%) | 14 (74%) |
| Anthracyclines | 21 (72%) | 10 (66%) | 11 (78%) |
| Immunotherapy (overall) | 4 (14%) | 2 (13%) | 2 (10%) |
| Avastin | 2 (50%) | 1 (50%) | 1 (50%) |
| Herceptin | 2 (50%) | 1 (50%) | 1 (50%) |
Values are presented as mean ± SD.